The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
NICE recommends lenalidomide in combination with rituximab for patients with previously treated FL
A novel combination therapy has been made available on the NHS for patients with previously treated follicular lymphoma (FL; Grade 1 –3A). In the final appraisal document, the National Institute for Care Excellence (NICE) recommended the combination of lenalidomide with rituximab (R2) for adult patients with relapsed or refractory (R/R) FL. The R2 regimen offers a chemotherapy-free treatment that will become immediately accessible to patients with R/R FL.1
The Lymphoma Hub reported results from the phase III AUGMENT trial (NCT01938001) which led to the U.S. Food & Drug Administration (FDA) and European Medicines Agency (EMA) approval of R2 in adult patients with R/R FL. Take a look at the Lymphoma Hub’s coverage of the AUGMENT study, FDA approval and EMA approval of R2.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content